Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight

(MENAFN- PR Newswire)

The high and growing incidence of tuberculosis (TB) cases globally, especially in high-burden countries, is a major driver for both the treatment drugs and diagnostics markets. TB remains a significant public health challenge, with millions of new cases reported each year, particularly in regions with limited access to healthcare and effective diagnostics.

LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's ' Tuberculosis Pipeline Insight 2025 ' report provides comprehensive global coverage of pipeline tuberculosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the tuberculosis pipeline domain.

Key Takeaways from the Tuberculosis Pipeline Report

• DelveInsight's tuberculosis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for tuberculosis treatment.
• Key tuberculosis companies such as Biofabri, Serum Institute of India Pvt. Ltd., Shanghai Jiatan Pharmatech, Sequella, Inc., LegoChem Biosciences, GlaxoSmithKline, BioVersys, BioNTech, SENTAN Pharma, ViChem, A&J Science, PDS Biotechnology, and others are evaluating new tuberculosis drugs to improve the treatment landscape.
• Promising tuberculosis pipeline therapies such as MTBVAC, VPM1002, WX-081, Sutezolid, LCB01-0371, GV118819, BVL-GSK098, BNT-164, SP0057, Research Program, AJ3, PDS0201, and others are under different phases of tuberculosis clinical trials.
• In May 2024, BioVersys announced the expansion of its strategic collaboration with the global biopharma company GSK to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).
• In March 2024, Bharat Biotech International Ltd announced the commencement of clinical trials for the Tuberculosis vaccine Mtbvac in adults in India.
• In December 2023, BioVersys announced that the US Food and Drug Administration had granted orphan-drug designation (ODD) to alpibectir (BVL-GSK098) and ethionamide fixed-dose combination for treatment of tuberculosis (TB).
• In May 2023, Biofabri a subsidiary of Zendal, and IAVI announced the signing of an agreement for end-to-end development of the tuberculosis (TB) vaccine candidate MTBVAC.
• In February 2023, Qurient and TB Alliance entered into a licensing agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.

Request a sample and discover the recent advances in tuberculosis treatment drugs @ Tuberculosis Pipeline Report

The tuberculosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage tuberculosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the tuberculosis clinical trial landscape.

Tuberculosis Overview

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a lethal infectious disease that has afflicted humanity for centuries, with traces found in ancient Egyptian mummies. Discovered by Robert Koch in 1882, the bacterium's genome was fully sequenced in 1998, paving the way for advancements in treatment. Despite the availability of the Bacille Calmette-Guérin (BCG) vaccine and effective short-course chemotherapy (DOTS), TB continues to pose a significant global health challenge, compounded by the rise of drug-resistant strains and its association with HIV. Declared a global emergency by the WHO in 1993, TB is challenging to diagnose, treat, and prevent due to Mtb's slow growth, dormancy, intricate cell structure, and ability to thrive inside host cells.

Prevention efforts are further hindered by poverty, overcrowding, and inadequate public health infrastructure, while non-specific symptoms, such as a persistent cough, contribute to its high transmission rate. TB spreads through the air when infected individuals cough, sneeze, or spit. Although a quarter of the world's population is infected, only 5-10% develop active TB, which is preventable and treatable but requires prolonged antibiotic therapy, straining even well-resourced healthcare systems.

Active TB manifests with symptoms such as persistent coughing, chest pain, fatigue, fever, night sweats, and weight loss. It can also present as extrapulmonary TB, which affects other organs and produces a range of symptoms. Symptoms vary across age groups, with children often displaying more subtle signs and infants showing more severe manifestations. Prompt diagnosis and strict adherence to an extended antibiotic regimen are essential to managing active TB and preventing its spread.

Diagnosing and treating TB requires a comprehensive approach. The diagnostic process begins with a detailed medical history and physical examination, followed by tests such as the tuberculin skin test (TST) or interferon-gamma release assay (IGRA) to identify latent TB. For active TB, tools like chest X-rays and sputum tests-including smear microscopy, culture, and molecular assays like the GeneXpert MTB/RIF-are crucial for detecting the bacterium.

Treatment for active TB typically involves a minimum six-month course of multiple antibiotics, including first-line drugs like isoniazid, rifampin, ethambutol, and pyrazinamide. Adherence to this regimen is critical to fully eliminate the bacteria and prevent the emergence of drug-resistant strains. Directly observed therapy (DOT), where healthcare workers supervise patients taking their medication, is often used to ensure compliance.

Drug-resistant TB requires second-line antibiotics and an extended treatment period, often accompanied by more severe side effects. Regular follow-ups with sputum tests and imaging are vital to monitor progress and address complications. Public health strategies, including contact tracing, BCG vaccination in high-risk regions, and improvements in living conditions, are crucial for controlling TB transmission. Ultimately, a combination of early diagnosis, effective treatment, and preventive measures is essential for reducing TB's impact on public health.

Find out more about tuberculosis treatment drugs @ Drugs for Tuberculosis Treatment

A snapshot of the Tuberculosis Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
MTBVAC	Biofabri	Phase III	Immunostimulants	Intradermal
VPM1002	Serum Institute of India Pvt. Ltd.	Phase III	Immunostimulants	Intradermal
WX-081	Shanghai Jiatan Pharmatech	Phase III	Adenosine triphosphatase inhibitors	Oral
Sutezolid	Sequella, Inc.	Phase II/III	Protein 30S ribosomal subunit inhibitors	Oral
LCB01-0371	LegoChem Biosciences	Phase II	Protein synthesis inhibitors	Oral
GV118819	GlaxoSmithKline	Phase II	Serine beta lactamase inhibitor	Oral
BVL-GSK098	BioVersys/GSK	Phase II	Ethionamide booster	Oral
BNT-164	BioNTech	Phase I	Immunostimulants	Intramuscular

Learn more about the emerging tuberculosis pipeline therapies @ Tuberculosis Clinical Trials

Tuberculosis Therapeutics Assessment

The tuberculosis pipeline report proffers an integral view of the tuberculosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Tuberculosis Pipeline Report

• Coverage : Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
• Therapeutics Assessment By Molecule Type : Monoclonal antibody, Small molecule, Peptide
• Therapeutics Assessment By Mechanism of Action: Immunostimulants, Adenosine triphosphatase inhibitors, Protein 30S ribosomal subunit inhibitors, Protein synthesis inhibitors, Serine beta lactamase inhibitor, Ethionamide booster
• Key Tuberculosis Companies : Biofabri, Serum Institute of India Pvt. Ltd., Shanghai Jiatan Pharmatech, Sequella, Inc., LegoChem Biosciences, GlaxoSmithKline, BioVersys, BioNTech, SENTAN Pharma, ViChem, A&J Science, PDS Biotechnology, and others
• Key Tuberculosis Pipeline Therapies : MTBVAC, VPM1002, WX-081, Sutezolid, LCB01-0371, GV118819, BVL-GSK098, BNT-164, SP0057, Research Program, AJ3, PDS0201, and others

Dive deep into rich insights for new drugs for tuberculosis treatment, visit @ Tuberculosis Drugs

Table of Contents

1.	Tuberculosis Pipeline Report Introduction
2.	Tuberculosis Pipeline Report Executive Summary
3.	Tuberculosis Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Tuberculosis Clinical Trial Therapeutics
6.	Tuberculosis Pipeline: Late-Stage Products (Pre-registration)
7.	Tuberculosis Pipeline: Late-Stage Products (Phase III)
8.	Tuberculosis Pipeline: Mid-Stage Products (Phase II)
9.	Tuberculosis Pipeline: Early-Stage Products (Phase I)
10.	Tuberculosis Pipeline Therapeutics Assessment
11.	Inactive Products in the Tuberculosis Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Tuberculosis Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the tuberculosis pipeline therapeutics, reach out @ Tuberculosis Treatment Drugs

Related Reports

Tuberculosis Market

Tuberculosis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key tuberculosis companies, including Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Aeras, Qurient Co., Sequella, Inc., Otsuka Pharmaceutical, Vaxil Biotherapeutics, Faron Pharmaceuticals, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, Spero Therapeutics, among others.

Pneumonia Market

Pneumonia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key pneumonia companies, including Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, among others.

Bacterial Pneumonia Market

Bacterial Pneumonia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key bacterial pneumonia companies, including Pfizer, Forecast Laboratories, Melinta Therapeutics Inc, Merck Sharp & Dohme LLC, Melinta Therapeutics Inc, Evopoint Biosciences Inc, Paratek Pharmaceuticals Inc, Wockhardt, Clarametyx Biosciences Inc, AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc, Bayer, among others.

Fungal Pneumonia Market

Fungal Pneumonia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key fungal pneumonia companies, including Gilead Sciences, Astellas Pharma, Pfizer, Merck & Co., Cidara Therapeutics, Basilea Pharmaceutica, Scynexis, Inc., F2G Ltd, Cidara Therapeutics, Basilea Pharmaceutica, Scynexis, Inc., Matinas BioPharma, Viamet Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

Contact Us

Shruti Thakur
[email protected]
+14699457679

Logo:

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN22012025003732001241ID1109119589